Lancor Scientific's chief operating officer Gopal Rao and chief medical officer Roland Schlesinger discuss with Proactive Investors some of the upcoming milestones for their Tumour Trace technology.
Roland Schlesinger's a specialist in health technology assessment - essentially analysing pharmaceuticals or medical technologies for efficiency and efficacy.
''The great thing about the technology is that we're looking for a quantifiable biomarker in the tissue - the hugely exciting thing about that is we're looking for a primary cancer, not a metastatic one, which means we're not catching it late we're very much catching it both early and even pre-early'', Rao says.
''We are absolutely able to reach an accuracy level of 98% definitely .... compared to others that are around 73-78%%'', Schlesinger says.
He adds: ''Also the time is very important - most procedures take days .. however with us we have results in less than three minutes''.